Ambrisentan use in a HIV-1 infected patient with end-stage renal disease and pulmonary hypertension : minimal removal by hemodialysis - a case report
Autor: | Santos, José Ramón, Merino Ribas, Ana, Haefeli, Walter E., Miranda, Cristina, Prats, Marisol, Bancu, Ioana, Bailón, Lucía, Moltó, José, Universitat Autònoma de Barcelona |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
medicine.medical_specialty Ambrisentan medicine.medical_treatment Hypertension Pulmonary 030106 microbiology 030232 urology & nephrology Urology HIV Infections Case Report lcsh:RC870-923 Pulmonary arterial hypertension Drug interactions End stage renal disease 03 medical and health sciences 0302 clinical medicine Renal Dialysis Internal medicine medicine Humans HIV-infection Darunavir Antihypertensive Agents Phenylpropionates business.industry Cobicistat Hepatitis C Chronic Middle Aged medicine.disease lcsh:Diseases of the genitourinary system. Urology Pulmonary hypertension Bosentan Tadalafil Hemodialysis Solutions Pyridazines Nephrology Hemodialysis Kidney Failure Chronic Female business medicine.drug |
Zdroj: | Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona BMC Nephrology Recercat: Dipósit de la Recerca de Catalunya Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) BMC Nephrology, Vol 21, Iss 1, Pp 1-4 (2020) r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname Recercat. Dipósit de la Recerca de Catalunya |
ISSN: | 1471-2369 |
Popis: | Background Ambrisentan is a selective endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). Little is known about ambrisentan removal by hemodialysis in patients with end-stage renal disease (ESRD). Case presentation A 53-year-old woman with HIV/hepatitis C virus (HCV) co-infection, PAH and ESRD on regular hemodialyis was admitted in our hospital due to refractory heart failure while on treatment with bosentan (125 mg twice daily) and tadalafil (20 mg once daily) for PAH and antiretroviral treatment (cART) including darunavir/cobicistat (800/150 mg once daily). Excessive exposure to bosentan due to drug interactions between bosentan and darunavir/cobicistat was suspected. Bosentan was replaced by ambrisentan, with progressive improvement in her clinical condition. Pre- and postdialyzer cocentrations of ambrisentan in plasma were determined and hemodialysis extraction ratio for ambrisentan was 2%. Conclusions Our results suggest that hemodialysis results in minimal ambrisentan removal, and therefore no specific ambrisentan dosage adjustment seems to be required in ESRD patients undergoing hemodialysis. |
Databáze: | OpenAIRE |
Externí odkaz: |